Ablynx

Merck strikes €20m deal with Ablynx for new generation cancer drugs

Ablynx, a Belgian biotechnology firm, has agreed to a €20 million deal with Merck to develop immunotherapies that can bolster the human body's potential to combat cancer cells, the Financial Times reported.

Read Full Article

Top deals of the Day - Bids, Mergers & Acquisitions

The following bids, mergers, acquisitions and disposals were reported on Monday including Forbes, Axel Springer, MidCap Financial LLC, Goldman Sachs and others.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics